Bod recorded its highest ever month of medicinal cannabis sales during April, filling 1,789 MediCabilis prescriptions in Australia, an 11% increase on the March figure and bringing the total for FY2021 to 9,519.
Bod filled around 27% of the 6,682 SAS-B prescriptions filled during the month, 64% of which were repeats, a trend which the company said enables it to “generate consistent and recurring revenue, and further highlights patient and physician product satisfaction”.
The company attributed the growth to ongoing engagement and strong relationships with approved prescribers, educational initiatives with physicians and healthcare professionals, and Bod’s Australia-wide clinical study to test the efficacy of MediCabilis to treat conditions including anxiety, insomnia and Post Traumatic Stress Disorder.
CEO Jo Patterson said: “MediCabilis volumes continue to grow at a very pleasing rate and the recent prescription sales growth further highlights Bod’s ability to generate strong revenues across one of the company’s two core operating divisions.
“The company has a number of new products in the pipeline that will be launched imminently.”